Give TGA more money, industry tells Australian government

31 January 2023

The life sciences industry in Australia has called for better funding for the country’s medicine and technology regulator.

Trade group Medicines Australia is leading the calls for more money for the Therapeutic Goods Administration (TGA) after the agency flagged increases in costs this year due to unexpected issues such as the regulation of cannabis and nicotine vaping products.

"93% of the TGA’s revenue is collected through fees and charges"Elizabeth de Somer, chief executive of Medicines Australia, wants to see some recognition of these challenges in the upcoming Federal Budget.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK